BRAINBox Solutions™ multi-modality approach is led by the leaders in the industry. It will include blood biomarker panels available on a point of care instrument and standard laboratory systems, as well as neurocognitive testing, to provide objective evidence of injury and prediction of patient recovery. Other relevant modalities will continue to be assessed.

BLOOD BIOMARKER PANELS

NEUROCOGNITIVE TESTING

POINT OF CARE INSTRUMENT
BRAINBox Solutions™ multi-modality approach will include blood biomarker panels, as well as neurocognitive testing, to provide objective evidence of injury and prediction of patient recovery. Other relevant modalities will continue to be assessed.
Latest News
Brainbox heads into pivotal trial of concussion diagnostic test with $23M in new funding
Click here to read the full article: Brainbox heads into pivotal trial of concussion diagnostic…
January 6, 2021
BRAINBox Solutions Announces Enrollment Begins in Pivotal, HeadSMART II Clinical Study of BRAINBox TBI Concussion Diagnostic and Prognostic Test
RICHMOND, VA. (December 16, 2020) ‐ BRAINBox Solutions today announced it is beginning enrollment…
December 16, 2020
BRAINBox Solutions Announces First Close in $23 Million in Series A Financing to Support Development and Pivotal Clinical Trial of ‘Breakthrough’ Concussion Diagnostic/Prognostic Test
Scott Gazelle, MD, PhD, MPH, FACR Appointed to Board of Directors and Damon Kuehl, MD, FACEP Joins…
December 8, 2020
View All
Donna J. Edmonds
CEO
Executive Management & Board Director
